Diagnostic Testing & Evaluations for CNTNAP2-Related DEE
At a Glance
CNTNAP2-related DEE is usually diagnosed by finding disease-causing changes in both copies of the CNTNAP2 gene, often through testing the child and both parents. MRI and EEG help evaluate brain structure and seizures, but normal or atypical results do not rule out the genetic diagnosis.
Confirming a diagnosis of CNTNAP2-related developmental and epileptic encephalopathy (DEE) is a multi-step process that combines genetic results with detailed brain imaging and electrical monitoring [1]. Because this condition is so rare, specialized testing is often required to distinguish it from other forms of epilepsy or developmental delay.
Genetic Testing: Finding the Cause
The primary way to diagnose this condition is through advanced genetic testing. Most families receive a diagnosis through Whole Exome Sequencing (WES) or Whole Genome Sequencing (WGS) [1][2]. These tests scan the “instructions” in your child’s DNA to find mutations in the CNTNAP2 gene.
- Trio Sequencing: It is highly recommended that both biological parents are tested alongside the child (called trio testing) [3]. This is crucial for confirming that the condition is biallelic, meaning the child inherited one mutated copy of the gene from each parent (known as being in trans) [4][5]. If parental testing is unavailable, the diagnosis can still be supported by the clinical picture and laboratory interpretation.
- Copy Number Variants (CNVs): Some genetic changes are not simple “spelling errors” but involve large missing or extra pieces of the gene. A test called a Chromosomal Microarray (CMA) or specific analysis within WGS is often needed to catch these CNVs [6][7].
- The Power of Reanalysis: If initial testing is negative but symptoms strongly suggest this condition, doctors may recommend reanalysis of the data 1–2 years later. As scientific knowledge grows, laboratories can often find answers in old data that were previously missed [8][9].
Specialized Brain Imaging (MRI)
While a standard brain MRI may sometimes look “normal,” specialists look for very specific signs in some children with CNTNAP2 mutations [10]. An MRI and EEG support clinical evaluation, but they are not strictly required to have classic abnormalities to confirm the diagnosis. A normal MRI or an atypical EEG does not invalidate the genetic findings.
- Bilateral Temporal Dysplasia: The most characteristic finding reported in some cohorts is a subtle abnormality in the temporal lobes on both sides of the brain [11].
- Gray-White Matter Blurring: Doctors look for a lack of clear definition between the brain’s “gray matter” (where neurons live) and “white matter” (the wiring). This “blurring” is a sign that the brain’s cortex did not form perfectly, a condition called cortical dysplasia [11][12].
- T2-FLAIR Hyperintensity: This is a technical term for “bright spots” seen on specific MRI sequences in the temporal lobe, indicating changes in the brain tissue [11].
EEG: Tracking the Seizures
An EEG (electroencephalogram) records the brain’s electrical activity and is essential for managing the “epileptic” part of the DEE. In this condition, the EEG often shows bilateral independent temporal onsets [11]. This means seizures can start on either the left or right side of the brain’s temporal region, often independently of each other [11].
Genetic vs. Autoimmune: A Critical Distinction
It is important to distinguish CNTNAP2-related DEE from CASPR2-antibody syndrome. While they involve the same protein, they are entirely different conditions:
- CNTNAP2-Related DEE: A genetic, lifelong condition caused by missing or broken instructions for the CASPR2 protein from birth [13].
- CASPR2-Antibody Syndrome: An autoimmune condition where the immune system mistakenly attacks the CASPR2 protein. While typically an “acquired” illness in older adults causing sudden confusion and memory loss (encephalitis), pediatric cases are possible and can present with seizures or psychiatric symptoms [13][14].
Your Genetic Report: A Completeness Checklist
When you receive your child’s lab report, ensure it contains the following details to be considered a complete diagnostic record:
| Checklist Item | What it means | Why it matters |
|---|---|---|
| Biallelic Confirmation | Confirms two mutations were found. | This condition is recessive and usually requires two variants [5]. |
| Inheritance Pattern | States the variants are “in trans.” | Proves one came from each parent, rather than both from one [4]. |
| Variant Classification | Labeled “Pathogenic” or “Likely Pathogenic.” | A “Variant of Uncertain Significance” (VUS) is not yet a definitive diagnosis [15]. |
| Methodology | States if WES, WGS, or Deletion/Duplication was used. | Helps you know if large-scale “missing pieces” (CNVs) were checked [7]. |
| Exact Variant Names | Codes like c.345G>A or p.Arg115His. | These “coordinates” allow you to track new research specific to your child’s mutation. |
If your report is missing these details, or if it only shows one mutation (monoallelic) or a VUS, you should discuss a follow-up plan with a neurogeneticist or genetic counselor, as a single variant does not definitively establish this diagnosis [15].
Common questions in this guide
What tests are used to diagnose CNTNAP2-related DEE?
Why should both biological parents be tested for CNTNAP2-related DEE?
What does a VUS mean on a CNTNAP2 genetic report?
Can a child with CNTNAP2-related DEE have a normal brain MRI?
What can an EEG show in CNTNAP2-related DEE?
What should be included in a child's CNTNAP2 genetic report?
How is CNTNAP2-related DEE different from CASPR2-antibody syndrome?
Get notified when new evidence is published on CNTNAP2-related developmental and epileptic encephalopathy.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (15)
- 1
Genetic Testing in Pediatric Epilepsy: Tools, Tips, and Navigating the Traps.
Chowdhury SR, Whitney R, RamachandranNair R, et al.
Pediatric neurology 2024; (157()):42-49 doi:10.1016/j.pediatrneurol.2024.05.008.
PMID: 38865949 - 2
Genetic testing for diagnosing neurodevelopmental disorders and epilepsy: a systematic review and meta-analysis.
Chang YM, Huang YT, Lai PC
Systematic reviews 2025; (14(1)):155 doi:10.1186/s13643-025-02896-y.
PMID: 40722196 - 3
Genome sequencing boosts diagnostic yield for the developmental and epileptic encephalopathies.
Munro JE, Thiyagarajah H, Bennett MF, et al.
medRxiv : the preprint server for health sciences 2026; doi:10.64898/2026.04.24.26351703.
PMID: 42094173 - 4
Hyperkinetic stereotyped movements in a boy with biallelic CNTNAP2 variants.
Scala M, Anijs M, Battini R, et al.
Italian journal of pediatrics 2021; (47(1)):208 doi:10.1186/s13052-021-01162-w.
PMID: 34641913 - 5
Genotype-phenotype correlation in contactin-associated protein-like 2 (CNTNAP-2) developmental disorder.
D'Onofrio G, Accogli A, Severino M, et al.
Human genetics 2023; (142(7)):909-925 doi:10.1007/s00439-023-02552-2.
PMID: 37183190 - 6
Diagnostic yield and copy number variants findings in 219 adult patients with developmental and epileptic encephalopathy.
Licchetta L, Bruschi G, Giangregorio T, et al.
Epilepsia 2026; (67(9)):e141-e149 doi:10.1002/epi.70360.
PMID: 42400436 - 7
Whole genome sequencing for copy number variant detection to improve diagnosis and management of rare diseases.
Bowman P, Grimes H, Dallosso AR, et al.
Developmental medicine and child neurology 2025; (67(1)):126-131 doi:10.1111/dmcn.15985.
PMID: 38840441 - 8
Reanalysis of whole-exome sequencing (WES) data of children with neurodevelopmental disorders in a standard patient care context.
van Slobbe M, van Haeringen A, Vissers LELM, et al.
European journal of pediatrics 2024; (183(1)):345-355 doi:10.1007/s00431-023-05279-4.
PMID: 37889289 - 9
Clinical next generation sequencing in developmental and epileptic encephalopathies: Diagnostic relevance of data re-analysis and variants re-interpretation.
Salinas V, Martínez N, Maturo JP, et al.
European journal of medical genetics 2021; (64(12)):104363 doi:10.1016/j.ejmg.2021.104363.
PMID: 34673242 - 10
Eight further individuals with intellectual disability and epilepsy carrying bi-allelic CNTNAP2 aberrations allow delineation of the mutational and phenotypic spectrum.
Smogavec M, Cleall A, Hoyer J, et al.
Journal of medical genetics 2016; (53(12)):820-827 doi:10.1136/jmedgenet-2016-103880.
PMID: 27439707 - 11
Bilateral temporal lobe dysplasia and seizure onset associated with biallelic CNTNAP2 variants.
Panza N, Bianchini C, Cetica V, et al.
Epilepsia open 2024; (9(1)):417-423 doi:10.1002/epi4.12843.
PMID: 37805811 - 12
Exploring the clinical spectrum of CNTNAP2-related neurodevelopmental disorders: A case series and a literature appraisal.
Barcia G, Scorrano G, Rio M, et al.
European journal of medical genetics 2024; (72()):104979 doi:10.1016/j.ejmg.2024.104979.
PMID: 39423951 - 13
Contactin-associated protein-like 2, a protein of the neurexin family involved in several human diseases.
Saint-Martin M, Joubert B, Pellier-Monnin V, et al.
The European journal of neuroscience 2018; (48(3)):1906-1923 doi:10.1111/ejn.14081.
PMID: 30028556 - 14
The clinical spectrum of Caspr2 antibody-associated disease.
van Sonderen A, Ariño H, Petit-Pedrol M, et al.
Neurology 2016; (87(5)):521-8 doi:10.1212/WNL.0000000000002917.
PMID: 27371488 - 15
Clinical Interpretation of Genetic Testing in Pediatric Pulmonary Arterial Hypertension: From Molecular Findings to Action.
Zheng X, Hua Y
Clinical genetics 2026; doi:10.1111/cge.70266.
PMID: 42986052
This page explains diagnostic testing for CNTNAP2-related DEE for informational purposes only and is not medical advice. A neurogeneticist, neurologist, or genetic counselor should interpret your child's results and recommend next steps.